CUREVAC NV (CVAC) Stock Fundamental Analysis
NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to CVAC. CVAC was compared to 572 industry peers in the Biotechnology industry. CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CVAC is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, CVAC could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year CVAC was profitable.
In the past year CVAC had a positive cash flow from operations.
In the past 5 years CVAC always reported negative net income.
CVAC had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CVAC has a better Return On Assets (12.68%) than 97.34% of its industry peers.
CVAC's Return On Equity of 14.94% is amongst the best of the industry. CVAC outperforms 96.63% of its industry peers.
CVAC has a better Return On Invested Capital (13.75%) than 96.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.68% | ||
| ROE | 14.94% | ||
| ROIC | 13.75% |
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVAC's Profit Margin of 19.93% is amongst the best of the industry. CVAC outperforms 96.98% of its industry peers.
With an excellent Operating Margin value of 24.34%, CVAC belongs to the best of the industry, outperforming 96.80% of the companies in the same industry.
Looking at the Gross Margin, with a value of 70.93%, CVAC belongs to the top of the industry, outperforming 83.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 19.93% | ||
| GM | 70.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CVAC is creating value.
The number of shares outstanding for CVAC has been increased compared to 1 year ago.
Compared to 5 years ago, CVAC has more shares outstanding
The debt/assets ratio for CVAC is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.24 indicates that CVAC is not in any danger for bankruptcy at the moment.
CVAC's Altman-Z score of 6.24 is amongst the best of the industry. CVAC outperforms 81.71% of its industry peers.
CVAC has a debt to FCF ratio of 0.42. This is a very positive value and a sign of high solvency as it would only need 0.42 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.42, CVAC belongs to the top of the industry, outperforming 96.27% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that CVAC is not too dependend on debt financing.
CVAC's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. CVAC is outperformed by 63.23% of its industry peers.
Even though the debt/equity ratio score it not favorable for CVAC, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.42 | ||
| Altman-Z | 6.24 |
ROIC/WACC2.04
WACC6.73%
2.3 Liquidity
A Current Ratio of 6.20 indicates that CVAC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.20, CVAC is in the better half of the industry, outperforming 62.52% of the companies in the same industry.
A Quick Ratio of 6.19 indicates that CVAC has no problem at all paying its short term obligations.
CVAC's Quick ratio of 6.19 is fine compared to the rest of the industry. CVAC outperforms 62.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.19 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 134.53%, which is quite impressive.
The Revenue has grown by 1166.88% in the past year. This is a very strong growth!
The Revenue has been growing by 33.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)134.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%781.82%
Revenue 1Y (TTM)1166.88%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%2896.43%
3.2 Future
Based on estimates for the next years, CVAC will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.02% on average per year.
The Revenue is expected to grow by 28.92% on average over the next years. This is a very strong growth
EPS Next Y164.54%
EPS Next 2Y25.04%
EPS Next 3Y20.69%
EPS Next 5Y9.02%
Revenue Next Year700.96%
Revenue Next 2Y7.81%
Revenue Next 3Y24.58%
Revenue Next 5Y28.92%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.60, the valuation of CVAC can be described as very cheap.
Based on the Price/Earnings ratio, CVAC is valued cheaply inside the industry as 98.40% of the companies are valued more expensively.
CVAC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.63.
CVAC is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.6 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CVAC is valued cheaper than 98.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.5 | ||
| EV/EBITDA | 1.22 |
4.3 Compensation for Growth
CVAC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CVAC's earnings are expected to grow with 20.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y25.04%
EPS Next 3Y20.69%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.3
+0.02 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners20.2%
Inst Owner Change-15.77%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap740.32M
Analysts78.57
Price Target7.87 (138.48%)
Short Float %2.96%
Short Ratio4.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)71.53%
Min EPS beat(2)-18.39%
Max EPS beat(2)161.44%
EPS beat(4)1
Avg EPS beat(4)0.77%
Min EPS beat(4)-106.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-10.4%
EPS beat(12)6
Avg EPS beat(12)7.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)263.4%
Min Revenue beat(2)160.16%
Max Revenue beat(2)366.65%
Revenue beat(4)3
Avg Revenue beat(4)123.3%
Min Revenue beat(4)-34.43%
Max Revenue beat(4)366.65%
Revenue beat(8)3
Avg Revenue beat(8)45.65%
Revenue beat(12)6
Avg Revenue beat(12)67.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.39%
EPS NY rev (1m)0%
EPS NY rev (3m)378.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-54.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)276.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.6 | ||
| Fwd PE | N/A | ||
| P/S | 1.3 | ||
| P/FCF | 7.5 | ||
| P/OCF | 5.68 | ||
| P/B | 0.98 | ||
| P/tB | 1.01 | ||
| EV/EBITDA | 1.22 |
EPS(TTM)0.5
EY15.15%
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)0.44
FCFY13.33%
OCF(TTM)0.58
OCFY17.61%
SpS2.53
BVpS3.37
TBVpS3.25
PEG (NY)0.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.68% | ||
| ROE | 14.94% | ||
| ROCE | 17.4% | ||
| ROIC | 13.75% | ||
| ROICexc | 50.97% | ||
| ROICexgc | 58.45% | ||
| OM | 24.34% | ||
| PM (TTM) | 19.93% | ||
| GM | 70.93% | ||
| FCFM | 17.4% |
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.42 | ||
| Debt/EBITDA | 0.23 | ||
| Cap/Depr | 147.78% | ||
| Cap/Sales | 5.57% | ||
| Interest Coverage | 65.13 | ||
| Cash Conversion | 81.73% | ||
| Profit Quality | 87.29% | ||
| Current Ratio | 6.2 | ||
| Quick Ratio | 6.19 | ||
| Altman-Z | 6.24 |
F-Score9
WACC6.73%
ROIC/WACC2.04
Cap/Depr(3y)481.31%
Cap/Depr(5y)411.27%
Cap/Sales(3y)121.71%
Cap/Sales(5y)106.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)134.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%781.82%
EPS Next Y164.54%
EPS Next 2Y25.04%
EPS Next 3Y20.69%
EPS Next 5Y9.02%
Revenue 1Y (TTM)1166.88%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Sales Q2Q%2896.43%
Revenue Next Year700.96%
Revenue Next 2Y7.81%
Revenue Next 3Y24.58%
Revenue Next 5Y28.92%
EBIT growth 1Y142.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.38%
EBIT Next 3Y18.73%
EBIT Next 5Y24.53%
FCF growth 1Y117.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.71%
OCF growth 3YN/A
OCF growth 5YN/A